Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dichlormezanone SCHEMBL29854540 | 1.00 | LMNA (0.72) | LMNATHRBAPEX1PMP22TSHR | |
| Chlormezanone SCHEMBL117870 | 0.84 | LMNA (1.00) | LMNATHRBAPEX1PMP22TSHR | |
| Chlormezanone SCHEMBL217864 | 0.84 | LMNA (1.00) | LMNATHRBAPEX1PMP22TSHR | |
| SCHEMBL11612098 | 0.65 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4136689 | 0.62 | BACE1 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL6028322 | 0.62 | BACE1 (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL8437322 | 0.60 | NPSR1 (0.49) | LMNATSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22817119 | 0.60 | ESR2 (0.53) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1824340 | 0.60 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL11822649 | 0.59 | SLC6A2 (0.42) | LMNAPMP22TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20220259165-A1 | S-OXIDES OF 2,3-DIARYL-2,3-DIHYDRO-4H-1,3-THIAZIN-4-ONES AND 2,3-DIARYL-1,3-THIAZEPAN-4-ONES AND METHODS FOR MAKING | THE PENN STATE RESEARCH FOUNDATION | 2022-08-18 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2020231873-A1 | S-OXIDES OF 2,3-DIARYL-2,3-DIHYDRO-4H-1,3-THIAZIN-4-ONES AND 2,3-DIARYL-1,3-THIAZEPAN-4-ONES AND METHODS FOR MAKING | THE PENN STATE RESEARCH FOUNDATION (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020231873-A1 | S-OXIDES OF 2,3-DIARYL-2,3-DIHYDRO-4H-1,3-THIAZIN-4-ONES AND 2,3-DIARYL-1,3-THIAZEPAN-4-ONES AND METHODS FOR MAKING | THE PENN STATE RESEARCH FOUNDATION (US) | 2020-11-19 | — | — | WO | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | LMNA 1461/4885THRB 3342/4885APEX1 295/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | LMNA 1180/4885THRB 1846/4885APEX1 803/4885 |
| US-20220259165-A1 | S-OXIDES OF 2,3-DIARYL-2,3-DIHYDRO-4H-1,3-THIAZIN-4-ONES AND 2,3-DIARYL-1,3-THIAZEPAN-4-ONES AND METHODS FOR MAKING | CBR3, SHROOM3, NOX3 | LMNA 4121/4885THRB 486/4885APEX1 2076/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | LMNA 1552/4885THRB 3075/4885APEX1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.